about
A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant.Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer.The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?Expression of receptor for advanced glycation end products in sarcoid granulomas.Erratum to "factors influencing oxidative imbalance in pulmonary fibrosis: an immunohistochemical study".GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders.Laboratory diagnosis of alpha1-antitrypsin deficiency.Screening for Alpha 1 antitrypsin deficiency in Tunisian subjects with obstructive lung disease: a feasibility report.Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.Therapy options in pulmonary alveolar proteinosis.Facts and promises on lung biomarkers in interstitial lung diseases.Lung disease caused by ABCA3 mutations.Incomplete expression of epithelial-mesenchymal transition markers in idiopathic pulmonary fibrosis.Factors influencing oxidative imbalance in pulmonary fibrosis: an immunohistochemical study.Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency.CR1 gene polymorphism in Finland.Evaluation of gene expression in human lymphocytes activated in the presence of melatonin.The problems of clinical trials and registries in rare diseases.Secondary outputs of alpha1-antitrypsin deficiency targeted detection programme.Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD.-374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis.The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.Identification of a novel alpha1-antitrypsin null variant (Q0Cairo).Complement C4A and C4B Gene Copy Number Study in Alzheimer's Disease Patients.Relationship between diffuse pulmonary fibrosis, alveolar proteinosis, and granulocyte-macrophage colony stimulating factor autoantibodies.A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis.Macrophage migration inhibitory factor in lung tissue of idiopathic pulmonary fibrosis patients.Plasmapheresis for treatment of pulmonary alveolar proteinosisSERPINA1 Gene Variants in Individuals from the General Population with Reduced 1-Antitrypsin ConcentrationsValidation of a Rapid, Simple Method to Measure 1-Antitrypsin in Human Dried Blood SpotsA Novel Method for Rapid Genotypic Identification of Alpha 1-Antitrypsin VariantsEight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasisThe influence of genetics on therapeutic developments in pulmonary alveolar proteinosisPulmonary alveolar proteinosis
P50
Q30578066-A5EA4902-B5F0-4E25-AAC0-5871F95BC0FBQ33668104-EFC71BBD-DF84-4E2D-99C7-F5BFC2170FD2Q34561697-67188819-C6EF-49CB-A79F-60008B870960Q34591271-CCB0FD34-D1EA-4937-B6A4-C1D305936D63Q35184324-3EED4A7A-F6BB-4992-8C1B-343F8007E32EQ35743114-3EC791D9-FFA7-427F-911A-E4F8F3AAFF0CQ36983169-3ADFD346-966E-4363-A780-DDC6C00C97A5Q37166417-8F30C757-C70E-4EEA-86FE-DE949494E565Q37221432-C89550D6-0344-435F-8105-3AEC6A0AEA35Q37774483-9B96CDE2-F470-406B-A25A-BE210E54A6DFQ38543042-168DEDD4-B6E7-4500-AD00-02CF3F3B9B93Q40625204-36511223-F020-46E1-907B-5DCAD0180E8EQ42492267-8F41C1CB-D563-4B0C-8256-C4370D56F234Q42747959-81A652CC-0019-4C6D-BF2B-D8AB0B318842Q43073325-103F3788-2414-4B60-AF2A-499D69804776Q44073074-97B306A7-249C-480C-B180-B23656C3D787Q44109248-9B5CDF6F-640C-4722-BF6A-12E128F663F0Q44299682-19FA834E-3A07-4A42-B085-AE157390EC6EQ44389625-76E27959-B4D4-4B32-BE7E-24629EAE116BQ44504391-2B6F693E-9E78-4F3F-AB7F-FC666A4041F2Q45302546-AC117194-3D21-4E49-B195-F87A5007C3D7Q45819487-A67DBD55-F4C0-495D-9751-8DE7AB95AEFBQ48137229-F1CDD0B4-F5D3-471F-84ED-0D445CD9862AQ48471096-898B12F4-8A00-4EA5-8290-1ABAF83013FAQ51472354-A9CEC92C-EA96-4601-B0B9-8F1862CE8B3CQ51493887-15033D15-6A7E-4C39-BCA7-1E4A846FFE7FQ51502645-58CA3B1A-D5A4-499D-85FA-61262D26760DQ60922589-7EF8A022-3A5D-428C-9B6A-1AD0A4D65F10Q60922593-CB032068-F964-4891-8614-5CF0A282436DQ60922604-EA58C5FD-D66C-406C-B7AB-54231246D6A1Q60922611-9042EE75-C21B-4819-B8D7-ECB729538044Q91930878-356374D2-F877-4A67-B94D-FA26737E7A4BQ92324904-360175FA-8754-4F20-B379-A339286E1D06Q95410224-E275F253-D1F6-473B-84FE-A85397466441
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ilaria Campo
@ast
Ilaria Campo
@en
Ilaria Campo
@es
Ilaria Campo
@nl
Ilaria Campo
@sl
type
label
Ilaria Campo
@ast
Ilaria Campo
@en
Ilaria Campo
@es
Ilaria Campo
@nl
Ilaria Campo
@sl
prefLabel
Ilaria Campo
@ast
Ilaria Campo
@en
Ilaria Campo
@es
Ilaria Campo
@nl
Ilaria Campo
@sl
P1053
K-4129-2016
P106
P1153
6603003791
P21
P31
P3829
P496
0000-0002-4423-2482